Oncology Market Research & Commercial Insights | ZoomRx

Promotional messages go live unvalidated

Most brands don’t know whether their core messages land with oncologists until after launch — when changing course is expensive.

Congress readouts shift intent overnight

A single ASCO or ESMO presentation can move prescribing intent before your brand team has even landed home. Most research cycles aren’t built to keep pace.

Sales rep interactions are underoptimized

Oncologists are the most time-constrained HCPs in pharma. A rep interaction that leads with the wrong content doesn’t get a second chance.

HCP perception gaps surface too late

By the time brand teams see a perception problem in Rx data, they’ve already lost months of momentum. The gap between what oncologists think and what your team assumes is wider than it looks.

Metabolic

GLP-1s, diabetes, obesity — the fastest-growing TA in pharma. ZoomRx tracks brand dynamics, HCP adoption, and competitive intelligence across metabolic indications.

CNS

Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

CNS

Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

Metabolic

GLP-1s, diabetes, obesity — the fastest-growing TA in pharma. ZoomRx tracks brand dynamics, HCP adoption, and competitive intelligence across metabolic indications.

CNS

Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

CNS

Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

Metabolic

GLP-1s, diabetes, obesity — the fastest-growing TA in pharma. ZoomRx tracks brand dynamics, HCP adoption, and competitive intelligence across metabolic indications.

CNS

Neurology, psychiatry, and rare neurological conditions. ZoomRx supports pre-launch intelligence and brand tracking across the full CNS indication landscape.

Oncology (1)

Oncology Manufacturer Perception Report — Q2 2025

ASCO conference

ASCO 2025: ZoomRx 7th Annual Oncologist Survey

FiercePharmaArticle

Enhertu, Keytruda Lead Oncology HCP Marketing — Fierce Pharma

Which cancer types receive the most pharma promotional attention?

Breast cancer, non-small cell lung cancer (NSCLC), multiple myeloma, chronic lymphocytic leukemia (CLL), and prostate cancer — in that order. ZoomRx's analysis of 71,000+ HCP interactions between July 2024 and June 2025 found these five indications account for 49% of all oncology promotions, with the top 10 pharma companies responsible for approximately two-thirds of total oncology HCP promotional activity.

How do you choose an oncology market research partner?

Look for a partner with oncology-specific benchmarks built from real indication data, custom research tailored to your brand rather than a syndicated tracker, and one team covering HCP and patient research in a single workflow. ZoomRx is built for exactly this, with a benchmark database of 3,000+ oncology messages across 115+ brands and primary research spanning 40+ indications.

What oncology indications does ZoomRx have the most research depth in?

ZoomRx's research has the deepest coverage in the five indications that dominate oncology promotional activity: breast cancer (including HER2+, HER2-Low, and TNBC), non-small cell lung cancer, multiple myeloma, chronic lymphocytic leukemia, and prostate cancer. ZoomRx also covers emerging indications including glioma and metastatic pancreatic cancer, which oncologists in 2025 identified as the areas with the highest unmet clinical need.